ProQR Announces CTA Submission For Phase 1 Study Of AX-0810 Targeting NTCP
June 26 (Reuters) - ProQR Therapeutics NV PRQR.O:
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.